Supreme Court Rejects Merck’s Bid to Reinstate $2.5B Damage Award Against Rival

Wednesday, 20 January 2021, 17:09:53
The U.S. Supreme Court on Tuesday rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict it won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment. …
— Insurance Journal

Merck KGaA, Darmstadt, Germany Announces Update on the [email protected] Clinical Program Including Lung 037 Study

Wednesday, 20 January 2021, 16:04:00
DARMSTADT, Germany, Jan. 20, 2021 /PRNewswire/ — Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update on the Phase III [email protected] Lung 037 study and the extensive [email protected] clinical trial program for the…
— PR Newswire

Merck KGaA, GSK Suffer Lung Cancer Drug Setback

Wednesday, 20 January 2021, 15:27:31
Merck KGaA's drug development programme has suffered a setback with the most important clinical trial of its cancer drug hopeful bintrafusp alfa stopped because the treatment does not appear to work.
— CNN-News18

GlaxoSmithKline's $4B bispecific cancer drug alliance with Merck KGaA hits a setback with a trial flop for NSCLC

Wednesday, 20 January 2021, 14:48:37
Close to 2 years ago, GSK’s R&D team eagerly agreed to pay up to $4 billion-plus to ally itself with Merck KGaA on a mid-stage bispecific called bintrafusp alfa, which intrigued them with the combination of a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein. But today the
— Endpoints News

Merck makes good on big CV gamble with vericiguat nod — but competition will be fierce

Wednesday, 20 January 2021, 13:15:14
The results for Merck's leading heart drug fell short of what some cardiologists had hoped for, but they proved more than enough to convince the FDA, which handed down an approval Wednesday. The agency OK'd vericiguat, now marketed as Verquvo, for patients with heart failure, offering one of the first
— Endpoints News